1. Home
  2. Analysis
  3. Zofran
  4. Doxylamine-succinate

Zofran and Doxylamine succinate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Zofran (ondansetron hydrochloride) and Doxylamine succinate (doxylamine succinate). Common drug interactions include maternal exposure during pregnancy among females and haemangioma among males.

The phase IV clinical study analyzes what interactions people have when they take Zofran and Doxylamine succinate. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Zofran?

Zofran has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 94,987 Zofran users. Check the latest studies of Zofran.

What is Doxylamine succinate?

Doxylamine succinate has active ingredients of doxylamine succinate. It is often used in insomnia. eHealthMe is studying from 2,851 Doxylamine succinate users. Check the latest studies of Doxylamine succinate.

On Aug, 05, 2026

25 people who take Zofran and Doxylamine succinate together, and have interactions are studied.

Zofran and Doxylamine succinate drug interactions.

What are the common drug interactions of Zofran and Doxylamine Succinate, by gender? *:

female:

  1. Maternal exposure during pregnancy (use of substance during pregnancy)
  2. Constipation
  3. Diarrhoea
  4. Maternal exposure before pregnancy (use of substance before pregnancy)
  5. Blood pressure increased
  6. Full blood count decreased
  7. Haemoglobin decreased
  8. Headache (pain in head)
  9. Hospitalisation
  10. Laryngitis (inflammation of the larynx)

male:

  1. Haemangioma (noncancerous, abnormally dense collections of dilated small blood vessels that may occur in the skin or internal organs)
  2. Maternal exposure before pregnancy (use of substance before pregnancy)
  3. Fatigue (feeling of tiredness)
  4. Hydrocele
  5. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  6. Jaundice neonatal (yellowing of skin in neonate)
  7. Oesophageal candidiasis (fungal infection of oesophagus)
  8. Pulmonary hypertension (increase in blood pressure in the lung artery)
  9. Rash
  10. Stomatitis (inflammation of mucous membrane of mouth)

What are the common drug interactions of Zofran and Doxylamine Succinate, by age (0-1 to 60+)? *:

0-1:

  1. Haemangioma (noncancerous, abnormally dense collections of dilated small blood vessels that may occur in the skin or internal organs)
  2. Maternal exposure before pregnancy (use of substance before pregnancy)
  3. Maternal exposure during pregnancy (use of substance during pregnancy)
  4. Hydrocele
  5. Jaundice neonatal (yellowing of skin in neonate)

2-9:

n/a

10-19:

n/a

20-29:

  1. Laryngitis (inflammation of the larynx)
  2. Upper respiratory tract infection
  3. Infusion site extravasation (flow of (blood or lymph) from infusion site)
  4. Maternal exposure during pregnancy (use of substance during pregnancy)
  5. Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)

30-39:

  1. Maternal exposure during pregnancy (use of substance during pregnancy)
  2. Abdominal discomfort
  3. Abortion spontaneous (naturally occurring miscarriage)
  4. Constipation
  5. Disease recurrence
  6. Fall
  7. Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
  8. Maternal exposure before pregnancy (use of substance before pregnancy)
  9. Morning sickness (sickness in morning during pregnancy)
  10. Nasopharyngitis (inflammation of the nasopharynx)

40-49:

  1. Decreased appetite
  2. Diarrhoea
  3. Pneumonia

50-59:

  1. Drug abuse
  2. Myocarditis (inflammation of heart muscle myocardium)
  3. Pneumonia
  4. Dizziness

60+:

  1. Dehydration (dryness resulting from the removal of water)
  2. Hyperkalaemia (damage to or disease of the kidney)
  3. Influenza
  4. Brain contusion (a form of traumatic brain injury)
  5. Cardiac arrest
  6. Pulmonary hypertension (increase in blood pressure in the lung artery)
  7. Cardiac failure congestive
  8. Contusion (a type of hematoma of tissue in which capillaries)
  9. Sepsis (a severe blood infection that can lead to organ failure and death)

What are the existing conditions these people have? *

  1. Stress And Anxiety: 7 people, 28.00%
  2. Sleep Disorder: 7 people, 28.00%
  3. Pain: 7 people, 28.00%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 7 people, 28.00%
  5. Headache (pain in head): 6 people, 24.00%
  6. Nasopharyngitis (inflammation of the nasopharynx): 5 people, 20.00%
  7. Indigestion: 4 people, 16.00%
  8. Constipation: 4 people, 16.00%
  9. High Blood Cholesterol: 4 people, 16.00%
  10. High Blood Pressure: 4 people, 16.00%

* Approximation only. Some reports may have incomplete information.

Do you take Zofran and Doxylamine succinate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Zofran and Doxylamine succinate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zofran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Doxylamine succinate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zofran and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Doxylamine succinate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride and doxylamine succinate (the active ingredients of Zofran and Doxylamine succinate, respectively), and Zofran and Doxylamine succinate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.